Lancet
Orforglipron matches insulin glargine on cardiovascular safety
Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine controls.Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine controls.
Randomized trial in 2,749 peopleOrforglipron